Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Multiple Sclerosis and Related Disorders|February 15, 2022
Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum StudyEoin P Flanagan, Michael Levy, Eliezer Katz, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|February 4, 2006
A novel three-dose regimen of daclizumab in liver transplant recipients with hepatitis C: a pharmacokinetic and pharmacodynamic studyW Kenneth Washburn, Lewis W Teperman, Thomas G Heffron, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 7, 2024
Enhancing Kidney Transplantation and the Role of Xenografts: Report of a Scientific Workshop Sponsored by the National Kidney FoundationAndrew B Adams, Emily A Blumberg, John S Gill, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 17, 2017
Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose studyMark A Agius, Gabriela Klodowska-Duda, Maciej Maciejowski, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|October 31, 2007
Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 studyGoran B G Klintmalm, W Kenneth Washburn, Steven M Rudich, et al.
Arthritis Research & Therapy|June 9, 2016
Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose studyElena Schiopu, Soumya Chatterjee, Vivien Hsu, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 22, 2023
American Society of Transplant Surgeons-American Society of Transplantation report of FDA meeting on regulatory expectations for xenotransplantation productsAndrew Adams, Linda C Cendales, David K C Cooper, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|July 30, 2019
Neuromyelitis optica spectrum disorder: Patient experience and quality of lifeJanine Beekman, Aysha Keisler, Omar Pedraza, et al.
Multiple Sclerosis and Related Disorders|December 10, 2020
Neuromyelitis optica spectrum disorder in China: Quality of life and medical care experienceWenjuan Huang, Jingzi ZhangBao, Xuechun Chang, et al.
Clinical Transplantation|June 25, 2010
YSPSL (rPSGL-Ig) for improvement of early renal allograft function: a double-blind, placebo-controlled, multi-center Phase IIa studyA Osama Gaber, Shamkant Mulgaonkar, Barry D Kahan, et al.
Pageof 4